An application of propensity score matching using claims data

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 7, 2005, Pages 465-476

  Seeger, John D ^a,b   Williams, Paige L ^b   Walker, Alexander M ^a  

^a Ingenix Inc   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Claims data; Outcomes research; Pharmacoepidemiology; Propensity score

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; FOLLOW UP; HEALTH INSURANCE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; MAJOR CLINICAL STUDY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATA COLLECTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACEUTICAL SERVICES; PHARMACOEPIDEMIOLOGY; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; STATISTICS;

EID: 22244461866     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1062     Document Type: Article

References (25)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with Simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Summary of the second report of the National Cholesterol Education Program (NCEP). JAMA 1993; 269: 3015-3023.
8. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511.
9. Walker A, Alexander M. Observation and Inference: An Introduction to the Methods of Epidemiology. Epidemiology Resources, Inc.: Newton, MA, 1991.
10. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
11. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999; 150: 327-333.
12. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-763.
13. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002; 137: 693-695.
14. Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 2003; 92: 1447-1451.
15. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
16. Drake C, Fisher L. Prognostic models and the propensity score. Int J Epidemiol 1995; 24: 183-187.
17. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics 1996; 52: 249-264.
18. Hirano K, Imbens GW. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcomes Res Methodol 2001; 2: 259-278.
19. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003; 158: 280-287.
20. Greenland S. Quantifying biases in causal models: classical confounding vs collider-stratification bias. Epidemiology 2003; 14: 300-306.
21. Rubin DB, Thomas N. Combining propensity score matching with additional adjustments for prognostic covariates. J Am Stat Assoc 2000; 95: 573-585.
22. Robins JM, Mark SD, Newey WK. Estimating exposure effects by modeling the expectation of exposure conditional on confounders. Biometrics 1992; 48: 479-495.
23. Parsons LS. Reducing bias in a propensity score matched pair sample using greedy matching techniques. Proceedings of the 26th annual SAS users group international conference, Cary, NC. http://www2.sas.com/proceedings/sugi26/p214-26.pdf.
24. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11: 561-570.
25. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-560.